1. Home
  2. USIO vs BYSI Comparison

USIO vs BYSI Comparison

Compare USIO & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Usio Inc.

USIO

Usio Inc.

HOLD

Current Price

$2.21

Market Cap

50.2M

Sector

Finance

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

N/A

Current Price

$1.69

Market Cap

58.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
USIO
BYSI
Founded
1998
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.2M
58.4M
IPO Year
1999
2016

Fundamental Metrics

Financial Performance
Metric
USIO
BYSI
Price
$2.21
$1.69
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
119.9K
13.7K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$28,200,535.00
N/A
Revenue This Year
$12.15
N/A
Revenue Next Year
$8.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.69
N/A
52 Week Low
$1.03
$1.18
52 Week High
$2.23
$2.50

Technical Indicators

Market Signals
Indicator
USIO
BYSI
Relative Strength Index (RSI) 75.39 52.69
Support Level $1.36 $1.56
Resistance Level N/A $1.83
Average True Range (ATR) 0.13 0.09
MACD 0.04 -0.01
Stochastic Oscillator 88.71 50.00

Price Performance

Historical Comparison
USIO
BYSI

About USIO Usio Inc.

Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: